HCW Biologics Inc. (HCWB)
US — Healthcare Sector
Automate Your Wheel Strategy on HCWB
With Tiblio's Option Bot, you can configure your own wheel strategy including HCWB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HCWB
- Rev/Share 0.0323
- Book/Share -0.1916
- PB -25.3588
- Debt/Equity -0.7281
- CurrentRatio 0.0698
- ROIC -4.454
- MktCap 11729610.0
- FreeCF/Share -0.3194
- PFCF -0.822
- PE -8.7717
- Debt/Assets 0.2372
- DivYield 0
- ROE 3.1331
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
About HCW Biologics Inc. (HCWB)
- IPO Date 2021-07-20
- Website https://www.hcwbiologics.com
- Industry Biotechnology
- CEO Dr. Hing C. Wong Ph.D.
- Employees 36
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.